ABBV Articles, AbbVie Inc. - From 07/12/24

AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the conf...

The most recent trading session ended with AbbVie (NYSE: ABBV) standing at $169.91, reflecting a +1.05% shift from the previouse trading day's ...

The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to ma...

Merck (NYSE: MRK) and its partner Daiichi Sankyo announced that the FDA has issued a complete response letter ("CRL") to the biologics li...

On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneousl...

All? Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* t...

Tuesday, AbbVie Inc (NYSE:ABBV) announced it received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for ABBV-951 (f...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

On CNBC's “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management named NVIDIA Corporation (NASDAQ:NVDA) a...

This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's (NYSE: LLY) Alzheimer's disease drug, donanemab. Pfize...